New Research Studies Available! (January 2019 – Press Release)

This month we are happy to share some incredible opportunities from our sister organizations! Read more about new research studies currently open to enrollment that would give you or someone you know the unique opportunity to be at the forefront of lung cancer research.

This month we are happy to share some incredible opportunities from our sister organizations! Read more about new research studies currently open to enrollment that would give you or someone you know the unique opportunity to be at the forefront of lung cancer research.

LCMI-006 PDX Study Open to Enrollment

The Addario Lung Cancer Medical Institute (ALCMI), Christine Lovly, MD, PhD of Vanderbilt-Ingram Cancer Center, ROS1ders (a patient driven research group), and Champions Oncology are working together with the goal of learning more about the rare genetic mutation known as ROS1-fusion. The goal of this study is to understand what drives tumor development, response to therapies, and acquired resistance. With this knowledge, doctors and researchers will be able to develop new and more effective therapies to fight against this rare and under-studied mutation.

ROS1 rearrangements occur in 1 to 3 % percent of all cancers including lung, gastric and ovarian cancers, as well as melanoma, cholangiocarcinoma, glioblastoma and other cancers. ROS1 is an enzyme coded by the ROS1 gene. A gene fusion occurs when a gene abnormally breaks off and fuses with another gene to form a hybrid gene that can lead to cancer initiation and drive its growth.

A patient-derived xenograft, otherwise known as PDX model is created by implanting a fresh piece of tumor tissue from a procedure into an immunodeficient mouse. This allows the mouse to act as a "host" and grow the tumor in a way that is similar to the original human tumor. This study will result in a model that will help researchers understand the response and resistance of ROS1 positive cancer.

To participate in the study or for more information, call Nurse Alicia at 866-988-ROS1 (7671) or go to www.alcmi.net/ROS1PDXstudy.

LIBERTI - Liquid Biopsy Study Open to Enrollment

The Addario Lung Cancer Medical Institute (ALCMI), Drs. Ramaswamy Govindan and Daniel Morgensztern, and Inivata have launched a new clinical study. This study will use Inivata’s InVision liquid biopsy platform and ctDNA to determine which patients with early non-small cell lung cancer (NSCLC) need more treatment and which patients will benefit from surgery alone. Doctor’s with the study also hope to find if ctDNA testing can detect early signs of recurrence.

“We will test patients with early-stage NSCLC before surgery and up to five years after surgery to help predict which patients need further treatment and which are more likely to have been treated successfully with surgery alone,” said Ramaswamy Govindan, MD, an oncologist and professor of medicine at Washington University School of Medicine in St. Louis. “We also hope to study the utility of ctDNA testing for detecting early signs of recurrence.”

“The field of liquid biopsy, and ctDNA analysis specifically is undergoing rapid development and we’re only now beginning to see the potential of what we may be able to achieve,” said Professor Clive Morris, chief medical officer of Inivata. “Studies like this are imperative for lung cancer management as they allow us to have much greater access to important genomic information that will drive more informed treatment decisions with a goal of providing better care to patients.”

The LIBERTI (Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation) study will recruit up to 500 patients from eight ALCMI member institutions in the U.S. The study is open to enrollment at Washington University in St. Louis and Northside Hospital in Atlanta. Contact Nurse Alicia at 203-768-9733 for more information.

Ready to collaborate with some of the top institutions in The United States to drive lung cancer research? Share these opportunities with others and participate today!

Together we can make a difference as we continue the fight to end lung cancer.

Sandra Shaw
Director, Patient Registry
Bonnie J. Addario Lung Cancer Foundation
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lungcancerregistry.org